

International conference on

CANNABIS AND MEDICINAL RESEARCH

November 15-16, 2018 Osaka, Japan



Jeremy Riggle

*Mary's Medicinals, USA**Mary's Nutritionals, USA*

The potential role of cannabinoids in healing cosmetic products

The Endo Cannabinoid System (ECS), discovered at the end of the 20th century, is a G-protein coupled receptor system involved in a number of physiological processes including pain sensation, metabolism, immunomodulation and inflammation. The ECS consists of Cannabinoid Receptor 1 (CB1), primarily found in the central nervous system and Cannabinoid Receptor 2 (CB2), found predominantly in the lymphatic system. In addition to CB1 and CB2 receptors, there are also endo-cannabinoids and associated enzymes responsible for their synthesis and degradation that the body produces naturally. Phytocannabinoids have been found to modulate and influence ECS tone, with the two most well-known compounds being Δ^9 -Tetrahydrocannabinol (THC) and Cannabidiol (CBD). This receptor system, including the endocannabinoids and their synthesis/degradation enzymes, is also found in virtually all human skin cell types, indicating a significant role of the ECS in skin pathophysiology.

Biography

Jeremy Riggle has received his PhD in Analytical Chemistry from the University of Idaho in Moscow, after being awarded MS in Environmental Chemistry also from the University of Idaho and a BS in Biology from Eastern Oregon University in La Grande, USA. He has then worked in the Division of Atmospheric Sciences at Desert Research Institute in Reno, NV, where he focused on the characterization and source apportionment of carbonaceous particulate matter. Following his time at DRI, he worked in the Food Safety and Environmental Stewardship Laboratory at Oregon State University in Corvallis, a toxicology lab where he concentrated on the environmental fate of polynuclear aromatic hydrocarbons. He was an Associate Professor of Chemistry in the Department of Chemistry & Biochemistry at his alma mater, Eastern Oregon University. Shortly after arriving at EOU, he co-founded EOA, a cannabis research and quality control laboratory and, prior to joining Mary's, spent the past several years focusing on the analytics of cannabis, its associated compounds and various cannabinoid formulations.

jeremy@marysmedicinals.com

Notes: